I'm LongbridgeAI, I can summarize articles.Cipher Pharmaceuticals reported a 32% drop in Q2 FY26 net income to US$4 million and a 10% revenue decline to US$12.1 million, driven by a 19% fall in Natroba sales. Adjusted EBITDA weakened 10% to US$6.8 million, with gross margins down 1 percentage point. However, the Canadian segment showed growth, with portfolio revenue rising 12% to US$4.6 million, led by a 14% increase in Epuris sales. Management aims for Natroba performance improvement next quarter via Walmart stock programs.
- Cipher Pharmaceuticals membukukan laba bersih Q2 2026 sebesar USD 4 juta, turun 32% dari setahun sebelumnya; EPS dasar USD 0,16, turun 30%. * Revenue Q2 2026 turun 10% menjadi USD 12,1 juta, dipicu penurunan revenue Natroba 19% menjadi USD 6,3 juta. * Adjusted EBITDA (non-IFRS) Q2 2026 melemah 10% menjadi USD 6,8 juta; margin kotor turun 1 poin persentase menjadi 80%. * Segmen Kanada naik, dengan revenue portofolio Kanada tumbuh 12% menjadi USD 4,6 juta; penjualan Epuris naik 14% menjadi USD 4,1 juta. * Manajemen menargetkan perbaikan kinerja Natroba pada kuartal berikutnya, didukung program stok agar Natroba tersedia di Walmart AS. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cipher Pharmaceuticals Inc. published the original content used to generate this news brief on August 11, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here